To receive the Femtech World newsletter, sign up here.
News
LTS wins US$4.3m grant to develop contraceptive microneedle array patches
Compared to other existing long-acting forms, contraceptive microneedle array patches can be self-administered
The technology company LTS has bagged a US$4.3m grant from the Bill & Melinda Gates Foundation to develop contraceptive microneedle array patches (MAP) for women in low- and middle-income countries.
Poor access to contraceptives presents a significant burden for women living in low- and middle-income countries.
According to a 2022 study, one in 14 women worldwide who want to use contraceptives cannot access them. This amounts to an unmet need of 162 million women, the majority of whom live in sub-Saharan Africa and South Asia.
MAPs are an innovative drug delivery technology that offers advantages in comparison to established drug delivery applications for contraception such as fewer side effects and potentially improved bioavailability with therapeutic and cost benefits.
The MAP contraceptive is planned as a long-acting application. Compared to other existing long-acting forms, it can be self-administered, is discreet and does not require healthcare provider visits.
“The LTS MAP team is excited to have support from the Gates Foundation for the development of a long-acting contraceptive microneedle array patch with LTS”, said Dr Frank Theobald, head of MAP programme at LTS.
“LTS has made great progress recently with respect to pre-clinical and clinical data, taking major steps towards the up-scaling and commercialisation of the MAP technology. Based upon those progresses made, we would like to emphasise that our MAP technology is no longer a vision, but real alternative for drug delivery of small molecules, vaccines, biologics, and mRNA.
“Support from the foundation will help to develop the MAP technology further and bring it to the next level of maturity and it will allow women in low- and middle-income countries to get access to a reliable and effective way of contraception and improve their economic situation. That will support them in establishment of gender equality in their communities.”
Bas van Buijtenen, CEO of LTS, said: “At LTS, we care passionately about bringing patient friendly drug delivery to people worldwide. We are honoured to receive support from the Gates Foundation in creating solutions for populations that would otherwise be at risk of being left behind.
“With this programme, we aim to deliver improved access to contraception, boosting health and empowering women.”
LTS has also received funding from the Bill & Melinda Gates Foundation to support new formulation methods for mRNA, such as dissolvable microneedle array patches.
Insight
‘Rejuvenated’ eggs raise hopes for improved IVF outcomes
Scientists say they have ‘rejuvenated’ human eggs, in work that could improve IVF success rates for older women.
The team reports that an age-related defect causing genetic errors in embryos may be reversed by supplementing eggs with a key protein.
In eggs donated by fertility patients, microinjection of the protein cut the share showing the defect from 53 per cent to 29 per cent.
The findings were presented at the British Fertility Conference in Edinburgh by researchers from the Max Planck Institute for Multidisciplinary Sciences in Göttingen.
The technique is being commercialised by Ovo Labs, co-founded by professor Melina Schuh, who led the research.
The approach targets problems in meiosis, the process where eggs halve their genetic material before fertilisation.
In older eggs, chromosome pairs can loosen and separate too soon, leading to embryos with too many or too few chromosomes, known as aneuploidy.
The researchers found levels of a protein called Shugoshin 1, which helps hold chromosome pairs together, decline with age. Microinjections appeared to restore this “molecular glue” and reduce errors.
Professor Schuh said: “Overall we can nearly halve the number of eggs with [abnormal] chromosomes. That’s a very prominent improvement.
“Most women in their early 40s do have eggs, but nearly all of the eggs have incorrect chromosome numbers. This was the motivation for wanting to address this problem.
“What is really beautiful is that we identified a single protein that, with age, goes down, returned it to young levels and it has a big effect.
We are just restoring the younger situation again with this approach.
Declining egg quality is a major reason IVF success rates fall steeply with age.
UK figures show an average birth rate of 35 per cent per embryo transferred for patients under 35, dropping to 5 per cent for women aged 43 to 44.
Dr Agata Zielinska, co-founder and co-chief executive of Ovo Labs, said: “Currently, when it comes to female factor infertility, the only solution that’s available to most patients is trying IVF multiple times so that, cumulatively, your likelihood of success increases.
“What we envision is that many more women would be able to conceive within a single IVF cycle.”
The approach would not extend fertility beyond menopause.
The team is in talks with regulators about a clinical trial.
Dr Güneş Taylor, of the University of Edinburgh, who was not involved, said: “This is really important work because we need approaches that work for older eggs because that’s the point at which most women appear.
“If there’s a one-shot injection that substantially increases the number of eggs with properly organised chromosomes, that gives you a better starting point.”
Insight
Number and timing of children linked to biological ageing, study finds
News
NHS doctor urges women to complete three health checks every month
-
Features4 weeks agoCannabis compounds kill ovarian cancer without harming healthy cells, research finds
-
Insight4 weeks agoMeta removes dozens of abortion advice and queer advocacy accounts
-
Insight5 days ago2025: The year IVF innovation went from lab to life
-
News3 weeks agoCan biotech help close the fertility gap? Inside the race to improve egg quality
-
Features4 weeks agoUniversity of Leeds IVF spinout raises £3.5m
-
Wellness3 weeks agoAI-driven digital tool delivers sustained blood pressure reductions, study finds
-
Cancer4 weeks agoMenopausal hormone therapy may not increase breast cancer risk in women with BRCA mutations
-
News3 weeks agoAHA invests in AI aimed at cardiology’s gender bias problem








1 Comment